Darifenacin 7.5 Mg
Product Images NDC 70700-182

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Darifenacin 7.5 Mg (NDC 70700-182). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xiromed, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Darifenacin-label-15mg-30 (Darifenacin 15mg 30ct)

Darifenacin Extended-Release Tablets 15 mg label showing a white background with blue and green text. The label includes the proprietary name Darifenacin, dosage strength 15 mg, and indicates 30 tablets per package. Manufacturer Xiromed, LLC is noted, along with storage instructions and usage warnings. The label also displays a barcode, the NDC 70700-183-30, and states the product is made in the USA.*

FDA Label Image

Darifenacin-label-15mg-90 (Darifenacin 15mg 90ct)

Label for Darifenacin 15 mg Extended-Release Tablets showing the dosage strength and total count of 90 tablets. The label includes the NDC barcode and indicates the product is manufactured by Xiromed, LLC. Storage instructions and usage warnings are also partially visible.*

FDA Label Image

Darifenacin-label-7-5mg-30 (Darifenacin 7 5mg 30ct)

Label for Darifenacin Extended-Release Tablets 7.5 mg by Xiromed, LLC. The label indicates 30 tablets in the package and the NDC 70700-182-30. It includes dosage information stating each tablet contains 8.929 mg of darifenacin hydrobromide to provide 7.5 mg darifenacin, with a usual dose of one tablet daily. Storage instructions and manufacturer details are also provided.*

FDA Label Image

Darifenacin-label-7-5mg-90 (Darifenacin 7 5mg 90ct)

Darifenacin Extended-Release Tablets 7.5 mg label showing 90 tablets in the package. The label includes the National Drug Code (NDC) 70700-182-90 and indicates the product is for prescription use only (Rx only). Manufactured for Xiromed, LLC, Florham Park, NJ, with storage instructions and a barcode on the left.*

FDA Label Image

Fig 1 (Darifenacin Fig01)

A line chart showing mean darifenacin plasma concentration (ng/mL) over 24 hours post-dose for two dosage groups: 7.5 mg and 15 mg once daily (od). The 15 mg group has consistently higher plasma levels, peaking around 6 hours. Both groups show variability indicated by error bars, illustrating standard deviations.*

FDA Label Image

Fig 2a (Darifenacin Fig02)

A line graph titled 'Figure 2a, Study 1' showing the median reduction in incontinence episodes per week from baseline over 12 weeks. The x-axis represents time in weeks (0, 2, 6, 12), and the y-axis shows median reduction with 95% confidence intervals. Three lines with symbols represent placebo (circle), Darifenacin 7.5 mg (triangle), and Darifenacin 15 mg (square), illustrating greater reduction in incontinence episodes over time with increasing dose.*

FDA Label Image

Fig 2b (Darifenacin Fig03)

A line graph titled "Figure 2b, Study 2" showing median reduction in incontinence episodes per week over 12 weeks. The x-axis represents time in weeks (0, 2, 6, 12), and the y-axis shows median reduction and 95 percent confidence interval from baseline in incontinence episodes per week. Three lines are shown: placebo (circle markers), Darifenacin 7.5 mg (triangle markers), and Darifenacin 15 mg (square markers). The graph illustrates greater median reduction in incontinence episodes for Darifenacin 15 mg compared to 7.5 mg and placebo over time.*

FDA Label Image

Fig 2c (Darifenacin Fig04)

Line graph titled 'Figure 2c, Study 3' displaying median reduction and 95 percent confidence intervals in incontinence episodes per week from baseline over 12 weeks. The x-axis represents time in weeks (0, 2, 6, 12), and the y-axis shows median reduction from baseline. Two lines compare Placebo (circle markers) and Darifenacin 15 mg (square markers), with Darifenacin showing greater median reduction over time.*

FDA Label Image

Structural Image (Darifenacin Str)

Chemical structure of Darifenacin hydrobromide, the active ingredient in Darifenacin 15 mg, as presented in the image with the molecular framework including aromatic rings and heterocyclic components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.